A quality-of-life-oriented endpoint for comparing therapies.
An endpoint, time without symptoms of disease and toxicity of treatment (TWiST), is defined to provide a single measure of length and quality of survival. Time with subjective side effects of treatment and time with unpleasant symptoms of disease are subtracted from overall survival time to calculate TWiST for each patient. The purpose of this paper is to describe the construction of this endpoint, and to elaborate on its interpretation for patient care decision-making. Estimating the distribution of TWiST using actuarial methods is shown by simulation studies to be biased as a result of induced dependency between TWiST and its censoring distribution. Considering the distribution of TWiST accumulated within a specified time from start of therapy, L, allows one to reduce this bias by substituting estimated TWiST for censored values and provides a method to evaluate the "payback" period for early toxic effects. Quantile distance plots provide graphical representations for treatment comparisons. The analysis of Ludwig Trial III evaluating toxic adjuvant therapies versus a no-treatment control group for postmenopausal women with node-positive breast cancer illustrates the methodology.
Gelber
R D
RD
Division of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.
Gelman
R S
RS
Goldhirsch
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008433:Mathematics; D015233:Models, Statistical; D011788:Quality of Life
D000970:Antineoplastic Agents